II. Mechanism

  1. Extracellular CTLA4 fused to Fc of IgG1
  2. Inhibits CD28 to CD80/CD66 binding
  3. Increases T-Cell Activation threshold and inhibits T-Cell proliferation

III. Dosing

  1. IV infusion: 10 mg/kg to 500, 750 or 1000 mg over 30 minutes
  2. Initial: 0, 2 and 4 months and then every 4 months

IV. Indications

V. Contraindications

  1. Do not use with TNF Antagonist agent, and probably Anankira
  2. Live virus Vaccine within the last 3 months

Images: Related links to external sites (from Bing)

Related Studies

Ontology: abatacept (C1619966)

Definition (NCI) A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.
Concepts Amino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121)
MSH C468566
SnomedCT 421412005, 421777009
English Abatacept, Abatacept (product), Abatacept (substance), abatacept, ABATACEPT, abatacept (medication), abatacept [Chemical/Ingredient]
Spanish abatacept (sustancia), abatacept (producto), abatacept